Aday, Aaron W.
Everett, Brendan M.
Funding for this research was provided by:
National Institutes of Health (K12 HL133117)
Article History
First Online: 22 April 2019
Compliance with Ethical Standards
:
: Aaron W. Aday declares that he has no conflict of interest.Brendan M. Everett is a co-investigator and chair of the clinical endpoints committee for the PROMINENT trial. He also reports grants and personal fees from Novartis, and personal fees from Amgen, NIDDK, Roche Diagnostics, U.S. FDA, and UpToDate.
: This article does not contain any studies with human or animal subjects performed by any of the authors.